EXPERIMENTAL DRUG DEVELOPMENT CENTR

Company Type:

The Experimental Drug Development Centre (EDDC) is neither a factory nor a trading company. It is a national research and development institute focused on drug discovery and development.

Company Introduction:

The Experimental Drug Development Centre (EDDC) serves as Singapore's national platform for drug discovery and development. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC's primary mission is to translate groundbreaking scientific discoveries into novel drug candidates. It plays a pivotal role in bridging the gap between fundamental research and clinical application by identifying and developing innovative therapeutic solutions.

EDDC's core activities encompass the entire spectrum of early-stage drug discovery and development. This includes target validation, high-throughput screening for hit identification, lead optimization, and comprehensive preclinical development. The centre employs a multidisciplinary approach, integrating cutting-edge expertise in chemistry, biology, pharmacology, and bioinformatics.

The institution collaborates extensively with academic institutions, pharmaceutical companies, and biotechnology firms both locally and internationally. These partnerships are crucial for accelerating the development of new medicines to address unmet medical needs. EDDC's efforts are geared towards generating intellectual property and promising drug candidates that can be further advanced by industry partners, ultimately aiming to deliver tangible benefits to patients. It does not engage in large-scale pharmaceutical manufacturing or the commercial trading of finished drug products.

The Experimental Drug Development Centre (EDDC) in Singapore is a national drug discovery and development unit, rather than a commercial manufacturer or direct seller of finished pharmaceutical products.

EDDC's primary output consists of novel drug candidates and associated intellectual property. These candidates are developed from early research stages through to preclinical testing and often up to Phase 1 clinical trials. Their focus areas include oncology, infectious diseases, and metabolic disorders.

The "products" that EDDC generates are typically drug compounds or biological entities with therapeutic potential. These are then usually licensed out or partnered with pharmaceutical companies for further clinical development, manufacturing, and eventual commercialization. Therefore, EDDC does not directly sell drugs to consumers or healthcare providers. Their role is in the early-stage innovation and development pipeline.